Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication February 21, 2022
- Revision received May 10, 2022
- Published online December 1, 2022.
Article Versions
- previous version (May 19, 2022 - 13:06).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Andrea Galbiati*,1,
- Aureliano Zana*,1,
- Matilde Bocci1,
- Jacopo Millul1,
- Abdullah Elsayed1,2,
- Jacqueline Mock1,
- Dario Neri2,3 and
- Samuele Cazzamalli1
- 1Research and Development Department, Philochem AG, Otelfingen, Switzerland;
- 2Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland; and
- 3Philogen S.p.A., Siena, Italy
- For correspondence or reprints, contact Samuele Cazzamalli (samuele.cazzamalli{at}philochem.ch) or Dario Neri (neri{at}pharma.ethz.ch).
↵* Contributed equally to this work.
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors
- Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios
- Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics
- Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
- Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
- Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
- Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors